Information Provided By:
Fly News Breaks for June 13, 2018
AGN
Jun 13, 2018 | 12:26 EDT
Wells Fargo analyst David Maris said he was encouraged by the positive topline results reported by Allergan from the first of two Phase 3 studies of its glaucoma treatment Bimatoprost SR, which he believes will eventually strengthen the company's commercial glaucoma franchise. He projects Bimatoprost SR to enter the market in 2020 and grow to sales of $280M in 2022. Maris keeps an Outperform rating on Allergan shares.
News For AGN From the Last 2 Days
There are no results for your query AGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.